- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.
Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Pfizer CT.gov Call Center
- Número de teléfono: 1-800-718-1021
- Correo electrónico: ClinicalTrials.gov_Inquiries@pfizer.com
Ubicaciones de estudio
-
-
Quebec
-
Chicoutimi, Quebec, Canadá
- Reclutamiento
- Site CA01194
-
Montreal, Quebec, Canadá
- Reclutamiento
- Site CA01071
-
Montreal, Quebec, Canadá
- Reclutamiento
- Site CA01052
-
-
-
-
-
Daegu, Corea del Sur
- Reclutamiento
- Site KR01113
-
Seongnam-si, Corea del Sur
- Reclutamiento
- Site KR01063
-
Seoul, Corea del Sur
- Reclutamiento
- Site KR01065
-
Seoul, Corea del Sur
- Reclutamiento
- Site KR01084
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Reclutamiento
- Arkansas Urology
-
-
California
-
Santa Barbara, California, Estados Unidos, 93105
- Reclutamiento
- Samsun Clinic - Ridley-Tree Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Reclutamiento
- Rocky Mountain Cancer Center
-
-
Delaware
-
Newark, Delaware, Estados Unidos, 19713
- Reclutamiento
- Medical Oncology Hematology Consultants
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Reclutamiento
- Hope and Healing Clinical Research LLC
-
New Lenox, Illinois, Estados Unidos, 60451
- Reclutamiento
- Hope and Healing Clinical Research LLC
-
Niles, Illinois, Estados Unidos, 60714
- Reclutamiento
- Illinois Cancer Specialists
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46825
- Reclutamiento
- Fort Wayne Medical Oncology and Hematology
-
-
Michigan
-
Royal Oak, Michigan, Estados Unidos, 48073
- Reclutamiento
- Comprehensive Urology
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65201
- Reclutamiento
- Missouri Cancer Associates
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Siteman Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- Reclutamiento
- Comprehensive Cancer Centers of Nevada - Southwest
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Fairfield, Ohio, Estados Unidos, 45014
- Reclutamiento
- Oncology Hematology Care Clinical Trials, LLC
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Reclutamiento
- Williamette Valley Cancer Institute and Research Center
-
Tigard, Oregon, Estados Unidos, 97223
- Reclutamiento
- Compass Oncology - West
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Reclutamiento
- Texas Oncology
-
Tyler, Texas, Estados Unidos, 75702
- Reclutamiento
- Texas Oncology - Northeast Texas
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Reclutamiento
- University of Virginia Comprehensive Cancer Center
-
Norfolk, Virginia, Estados Unidos, 23502
- Reclutamiento
- Virginia Oncology Associates
-
-
-
-
-
Kaohsiung City, Taiwán
- Reclutamiento
- Site TW01117
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
- Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
- Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
- Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria:
- Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
- Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
- Prior pelvic radiation for any reason
- Inadequate bladder function
- Other active malignancies within 3 years prior to randomization
- Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
- Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
- Uncontrolled diabetes
- Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
- Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
- Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
- Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
- Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
- Active keratitis or corneal ulcerations
- History of autoimmune disease that has required systemic treatment in the past 2 years
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Prior allogeneic stem cell or solid organ transplant
- Received a live attenuated vaccine within 30 days prior to randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A
Enfortumab vedotin + pembrolizumab (EV + P) |
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.
Otros nombres:
IV infusion on Day 1 of every 3-week cycle up to cycle 17.
Otros nombres:
|
|
Comparador activo: Arm B
Concurrent Chemoradiotherapy (cCRT) |
64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes. 55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only. 40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation. 500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.
Otros nombres:
12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.
Otros nombres:
100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Periodo de tiempo: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Overall Survival (OS)
Periodo de tiempo: Up to approximately 60 months
|
Time from randomization to death due to any cause. |
Up to approximately 60 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Periodo de tiempo: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Periodo de tiempo: Up to approximately 60 months
|
cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology. |
Up to approximately 60 months
|
|
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Periodo de tiempo: Up to approximately 60 months]
|
Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first. |
Up to approximately 60 months]
|
|
Time to Cystectomy
Periodo de tiempo: Up to approximately 60 months
|
The time from randomization to cystectomy. |
Up to approximately 60 months
|
|
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Periodo de tiempo: Up to approximately 60 months
|
The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Cystectomy Free Survival (CFS)
Periodo de tiempo: Up to approximately 60 months
|
The time from randomization to cystectomy or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Periodo de tiempo: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
|
Number of Participants with Serious TEAEs
Periodo de tiempo: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Zejing Wang, MD/PhD, Pfizer
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Gemcitabina
- Neoplasias
- Neoplasias de la vejiga urinaria
- Carcinoma urotelial
- Cisplatino
- Pembrolizumab
- Fluorouracilo
- Complicaciones
- Enfermedades urológicas
- Cáncer urotelial
- Enfortumab vedotina
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias Urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales masculinas
- Cáncer de vejiga con invasión muscular
- Mitomicina
- Enfermedades de la vejiga urinaria
- Preservación de vejiga
- Enfermedades urogenitales
- Female Urogenital Diseases and Pregnancy
- Bladder-sparing
Términos MeSH relevantes adicionales
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Carcinoma
- Enfermedades urogenitales
- Neoplasias
- Enfermedades urológicas
- Neoplasias de la vejiga urinaria
- Neoplasias Urológicas
- Carcinoma De Células De Transición
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades urogenitales masculinas
- Enfermedades de la vejiga urinaria
- Enfermedades urogenitales femeninas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Terapéutica
- Indoles
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Desoxicitidina
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Uracílico
- Pirimidinonas
- Compuestos de platino
- Radioterapia
- Quinones
- Azirines
- Fraccionamiento de dosis, radiación
- Dosis de radioterapia
- Mitomicinas
- Indolequinonas
- Gemcitabina
- Fluorouracilo
- Cisplatino
- Mitomicina
- pembrolizumab
- Enfortumab Vedotin
- Hipofraccionamiento de dosis de radiación
Otros números de identificación del estudio
- C5701009
- EV-309 (Otro identificador: Alias Study Number)
- 2026-525612-34-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .